カテゴリ： GlobalData, アメリカ, 企業調査

Portola Pharmaceuticals Inc (PTLA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Portola Pharmaceuticals Inc (PTLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10083
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company’s products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc (PTLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 12
Partnerships 13
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 13
Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 14
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 15
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 16
Aciex Amends Research Agreement With Portola Pharma 17
Portola Pharma Expand Agreement with Lee’s Pharma 18
Licensing Agreements 19
Portola Pharma Enters into Licensing Agreement with SRX Cardio 19
Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 20
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 21
Equity Offering 23
Portola Pharma Raises USD401.6 Million in Public Offering of Shares 23
Portola Pharma Prices Public Offering of Shares for USD150 Million 25
Portola Pharma Prices Public Offering of Shares for USD100 Million 27
Portola Pharma Raises USD185.3 Million in Public Offering of Shares 29
Portola Pharma Completes Public Offering Of Shares For US$106 Million 31
Portola Pharma Completes IPO For US$140 Million 32
Portola Pharmaceuticals Inc – Key Competitors 34
Portola Pharmaceuticals Inc – Key Employees 35
Portola Pharmaceuticals Inc – Locations And Subsidiaries 36
Head Office 36
Recent Developments 37
Financial Announcements 37
Nov 07, 2018: Portola Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 37
Aug 09, 2018: Portola Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 39
May 09, 2018: Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 40
Feb 28, 2018: Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 42
Nov 06, 2017: Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 44
Aug 09, 2017: Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 45
May 08, 2017: Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 46
Feb 28, 2017: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 47
Corporate Communications 49
Sep 20, 2018: Portola Pharmaceuticals appoints Scott Garland President and Chief Executive Officer 49
Sep 07, 2018: Portola Pharmaceuticals announces resignation of Tao Fu as chief commercial officer 50
Aug 09, 2018: Portola Pharmaceuticals appoints Ernie Meyer as executive vice president and chief human resources officer 51
Jun 25, 2018: Portola Pharmaceuticals Names Glenn Brame as Senior Vice President of Technical Operations 52
Jun 04, 2018: Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018 53
Mar 12, 2018: Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel 54
Nov 06, 2017: Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President and Chief Medical Officer 55
Product News 56
11/30/2017: Portola Pharmaceuticals to Present New Data on Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting 56
Product Approvals 57
Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma 57
Clinical Trials 58
Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib 58
Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 60
Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 61
Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 62
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 63
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 64
Other Significant Developments 65
Oct 09, 2018: Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Portola Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 12
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 13
Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 14
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 15
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 16
Aciex Amends Research Agreement With Portola Pharma 17
Portola Pharma Expand Agreement with Lee’s Pharma 18
Portola Pharma Enters into Licensing Agreement with SRX Cardio 19
Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 20
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 21
Portola Pharma Raises USD401.6 Million in Public Offering of Shares 23
Portola Pharma Prices Public Offering of Shares for USD150 Million 25
Portola Pharma Prices Public Offering of Shares for USD100 Million 27
Portola Pharma Raises USD185.3 Million in Public Offering of Shares 29
Portola Pharma Completes Public Offering Of Shares For US$106 Million 31
Portola Pharma Completes IPO For US$140 Million 32
Portola Pharmaceuticals Inc, Key Competitors 34
Portola Pharmaceuticals Inc, Key Employees 35

List of Figures
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Portola Pharmaceuticals Inc (PTLA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Foundation Medicine Inc (FMI)：企業の財務・戦略的SWOT分析
    Summary Foundation Medicine Inc (Foundation Medicine) is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers, or hematolog …
  • Empyrean Energy PLC (EME)：石油・ガス：M&Aディール及び事業提携情報
    Summary Empyrean Energy PLC (Empyrean Energy) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company's projects include China Block 29/11 project, Duyung PSC project, and Sacramento Basin Projects. Its Duyung PSC project covers a …
  • Immune Pharmaceuticals Inc (IMNP)：企業の財務・戦略的SWOT分析
    Summary Immune Pharmaceuticals Inc (Immune Pharma) formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designed …
  • Konsortium Transnasional Berhad：戦略・SWOT・企業財務分析
    Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • United Energy Group Ltd (467)：企業の財務・戦略的SWOT分析
    Summary United Energy Group Ltd (UEG) is an independent upstream oil and gas company that offers exploration and production of oil and gas reserves. The company's activities include merger and acquisition of oil and natural gas assets, exploitation, development and production of crude oil and natura …
  • Armstrong Flooring Inc (AFI)：企業の財務・戦略的SWOT分析
    Armstrong Flooring Inc (AFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Qualcomm Incorporated (QCOM)-エネルギー分野：企業M&A・提携分析
    Summary Qualcomm Incorporated (Qualcomm) is a technology and communication company. The company designs and manufactures digital wireless telecommunications products and services. Qualcomm offers integrated circuits and system software for wireless mobile devices. The major technologies such as code …
  • Merit Medical Systems Inc (MMSI)：企業の財務・戦略的SWOT分析
    Merit Medical Systems Inc (MMSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Crescendo Bioscience Inc-医療機器分野：企業M&A・提携分析
    Summary Crescendo Bioscience Inc (Crescendo), a subsidiary of Myriad Genetics Inc is a molecular diagnostics company that concentrates on rheumatology. The company develops quantitative, objective, and biology based tests for rheumatologists. Its vectra DA is an advanced blood test for rheumatoid ar …
  • McCarthy & Stone Plc：企業の戦略・SWOT・財務情報
    McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report Summary McCarthy & Stone Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Siemens Healthineers.：戦略・SWOT・企業財務分析
    Siemens Healthineers. - Strategy, SWOT and Corporate Finance Report Summary Siemens Healthineers. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • HollyFrontier Corp (HFC)：企業の財務・戦略的SWOT分析
    HollyFrontier Corp (HFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bespak Europe Ltd：企業の製品パイプライン分析2018
    Summary Bespak Europe Ltd (Bespak), a subsidiary of Consort Medical plc is a medical device company that provides inhalation systems. The company provides products such as inhalation devices, injectables, medical check valves and nasal products. Its inhalation devices comprise dose counting actuator …
  • Canadian Natural Resources, Ltd.：企業の戦略・SWOT・財務分析
    Canadian Natural Resources, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Canadian Natural Resources, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SQI Diagnostics Inc (SQD)：企業の財務・戦略的SWOT分析
    Summary SQI Diagnostics Inc (SQI Diagnostics) is a diagnostic company that provides in vitro diagnostic and pharmaceutical research products. It provides products such as sqidworks, sqidlite and sqid-X. Its sqidworks system is used in labs. SQI Diagnostic’s sqidlite is a practical benchtop system. I …
  • Tribune Media Company：企業の戦略・SWOT・財務分析
    Tribune Media Company - Strategy, SWOT and Corporate Finance Report Summary Tribune Media Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Anika Therapeutics Inc (ANIK)：企業の財務・戦略的SWOT分析
    Anika Therapeutics Inc (ANIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Becton Dickinson and Co (BDX)：企業の財務・戦略的SWOT分析
    Becton Dickinson and Co (BDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • AirAsia Berhad：企業のM&A・事業提携・投資動向
    AirAsia Berhad - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AirAsia Berhad Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • easyJet Plc：企業の戦略・SWOT・財務情報
    easyJet Plc - Strategy, SWOT and Corporate Finance Report Summary easyJet Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆